Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International for $425M

Sanofi SNY announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. VRX, for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.